Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.450
-0.040 (-2.68%)
At close: Aug 1, 2025, 4:00 PM
1.440
-0.010 (-0.69%)
After-hours: Aug 1, 2025, 5:42 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $4.50, which forecasts a 210.34% increase in the stock price over the next year. The lowest target is $1.50 and the highest is $10.
Price Target: $4.50 (+210.34%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold → Buy Upgrades $2.5 → $3.5 | Hold → Buy | Upgrades | $2.5 → $3.5 | +141.38% | Jul 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +589.66% | May 9, 2025 |
| Morgan Stanley | Morgan Stanley | Sell Initiates $3 → $1.5 | Sell | Initiates | $3 → $1.5 | +3.45% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +382.76% | Feb 27, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $4 | Strong Buy → Hold | Downgrades | $4 | +175.86% | Dec 16, 2024 |
Financial Forecast
Revenue This Year
12.36M
from 100.56M
Decreased by -87.71%
Revenue Next Year
51.87M
from 12.36M
Increased by 319.82%
EPS This Year
-1.92
from -1.23
EPS Next Year
-1.65
from -1.92
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.0M | 211.5M | 242.1M | ||
| Avg | 12.4M | 51.9M | 119.3M | ||
| Low | 9.2M | 4.1M | 42.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -83.1% | 1,611.6% | 366.8% | ||
| Avg | -87.7% | 319.8% | 130.0% | ||
| Low | -90.9% | -66.6% | -17.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.51 | -0.90 | -0.74 | ||
| Avg | -1.92 | -1.65 | -1.02 | ||
| Low | -2.10 | -2.48 | -1.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.